4.6 Article

Idiopathic inflammatory myopathies

Journal

NATURE REVIEWS DISEASE PRIMERS
Volume 7, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41572-021-00321-x

Keywords

-

Funding

  1. Swedish Research Council
  2. Swedish Rheumatism Association
  3. King Gustav V 80-year Foundation
  4. Stockholm County Council (ALF Project)
  5. Czech Ministry of Health - Conceptual Development of Research Organization [00023728]
  6. Marianne and Marcus Wallenberg Foundation
  7. Professor Nanna Svartz Foundation
  8. King Gustaf V 80-year Foundation
  9. Intramural Research Program of the NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases
  10. Intramural Research Program of the NIH, National Institute of Environmental Health Sciences

Ask authors/readers for more resources

Idiopathic inflammatory myopathies, also known as myositis, are a group of autoimmune disorders with heterogeneous clinical manifestations and organ involvement. Different subtypes have varying prognoses, treatment responses, and organ manifestations, highlighting the importance of understanding the underlying pathophysiological mechanisms.
Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that IIM are systemic inflammatory disorders. Different myositis-specific auto-antibodies have been identified and, on the basis of clinical, histopathological and serological features, IIM can be classified into several subgroups - dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis. The prognoses, treatment responses and organ manifestations vary among these groups, implicating different pathophysiological mechanisms in each subtype. A deeper understanding of the molecular pathways underlying the pathogenesis and identifying the auto-antigens of the immune reactions in these subgroups is crucial to improving outcomes. New, more homogeneous subgroups defined by auto-antibodies may help define disease mechanisms and will also be important in future clinical trials for the development of targeted therapies and in identifying biomarkers to guide treatment decisions for the individual patient. Idiopathic inflammatory myopathies, also known as myositis, are a heterogeneous group of autoimmune disorders usually characterized by chronic inflammation of the muscle. This Primer reviews the epidemiology, pathophysiology, diagnosis, treatment, patient quality of life and future research needs of this group of diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available